Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Leishmaniasis

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.

Cryptococcal Meningitis

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dermoscopic Nail Disorders in School-Going Children.

Cureus·2023

Same author

Comparing Dermatoscopic Features With Slit Skin Smear and Histopathology in Diagnosis of Cutaneous Leishmaniasis.

Cureus·2023

Same author

The Association of HLA Alleles and Haplotypes with Age of Disease Onset in Pakistani Psoriatic Patients.

International archives of allergy and immunology·2022

Same author

Dermatology Residency Training in COVID-19 Pandemic: Transition from Traditional to Online Teaching.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2020

Same author

Harlequin Fetus in a Twin Pregnancy: An Extremely Rare Presentation.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2020

Same author

Cutaneous Leishmaniasis caused by L. Infantum.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2019

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

Miltefosine in cutaneous leishmaniasis.

Simeen Ber Rahman¹, Arfan ul Bari, Nadeem Mumtaz

¹Department of Dermatology, Military Hospital, Rawalpindi.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

|March 22, 2007

Summary

Oral Miltefosine demonstrated comparable efficacy to pentavalent antimony for cutaneous leishmaniasis treatment. This safe and effective oral option offers an advantage for patients and in regions with resistant parasites.

Area of Science:

Dermatology
Infectious Diseases
Pharmacology

Background:

Cutaneous leishmaniasis is a parasitic skin infection with limited treatment options.
Pentavalent antimony compounds are the standard treatment but have toxicity concerns.

Purpose of the Study:

To evaluate the efficacy of oral Miltefosine for cutaneous leishmaniasis.
To compare Miltefosine with pentavalent antimony, the current standard treatment.

Main Methods:

A non-randomized, open-label comparative trial involving 30 patients aged 12 years and older.
Patients received either oral Miltefosine (2.5mg/kg/day) or injectable pentavalent antimony (20mg/kg/day) for 28 days.
Efficacy was assessed by ulcer size, clinical improvement, and cure rates at 3 and 6 months post-treatment.

More Related Videos

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Related Experiment Videos

Last Updated: Jul 16, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Main Results:

Both treatments led to significant lesion improvement with minimal side effects.
At 3 months, cure rates were 93% for Miltefosine and 73.33% for pentavalent antimony.
At 6 months, cure rates were 86% for Miltefosine and 66.6% for pentavalent antimony, with no statistically significant difference between groups (p>0.5).

Conclusions:

Oral Miltefosine is a safe and effective alternative for cutaneous leishmaniasis.
Its oral administration is a significant advantage over injectable treatments.
Miltefosine may be beneficial in areas with parasite resistance to existing therapies.